We speculate that distinguishing HGBCL-DH-BCL6 from DLBCL, NOS may prove even more relevant in YA patients who are more likely to be eligible for and tolerate intensive chemotherapy regimens than older adults. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.